
TYK2 Inhibitor Deucravacitinib up for FDA Review for Psoriatic Arthritis
The FDA has accepted Bristol Myers Squibb’s supplemental New Drug Application (sNDA) for deucravacitinib for treating adults with active psoriatic arthritis (PsA) with a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.1 “All in all, this …